Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma.

[1]  J. García-Pedrero,et al.  Prognostic Significance of the Pluripotency Factors NANOG, SOX2, and OCT4 in Head and Neck Squamous Cell Carcinomas , 2020, Cancers.

[2]  M. Wink,et al.  Phytochemicals: Potential Lead Molecules for MDR Reversal , 2020, Frontiers in Pharmacology.

[3]  Jianmin Li,et al.  MARK2 enhances cisplatin resistance via PI3K/AKT/NF-κB signaling pathway in osteosarcoma cells. , 2020, American journal of translational research.

[4]  Wen Peng,et al.  Targeting cancer stem cell pathways for cancer therapy. , 2020, Signal transduction and targeted therapy.

[5]  A. Przybyłkowski,et al.  The MDR1/ABCB1 gene rs 1045642 polymorphism in colorectal cancer , 2019, Archives of medical science : AMS.

[6]  B. Baradaran,et al.  microRNA-181 serves as a dual-role regulator in the development of human cancers. , 2019, Free radical biology & medicine.

[7]  Yi Cheng,et al.  Knockdown Of lncRNA NCK-AS1 Regulates Cisplatin Resistance Through Modulating miR-137 In Osteosarcoma Cells , 2019, OncoTargets and therapy.

[8]  Chih-ping Chen,et al.  Detection of a familial 1q21.1 microdeletion and concomitant CHD1L mutation in a fetus with oligohydramnios and bilateral renal dysplasia on prenatal ultrasound. , 2019, Taiwanese journal of obstetrics & gynecology.

[9]  S. Pignata,et al.  Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications , 2019, Cancers.

[10]  Wei Liu,et al.  Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p , 2019, Medical science monitor : international medical journal of experimental and clinical research.

[11]  P. Duijf,et al.  MicroRNAs in cancer cell death pathways: Apoptosis and necroptosis. , 2019, Free radical biology & medicine.

[12]  Min Liu,et al.  INPP4B exerts a dual function in the stemness of colorectal cancer stem-like cells through regulating Sox2 and Nanog expression. , 2019, Carcinogenesis.

[13]  K. Shen,et al.  CHD1L promotes cell cycle progression and cell motility by up-regulating MDM2 in breast cancer. , 2019, American journal of translational research.

[14]  Yuekui Jian,et al.  lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT pathway. , 2019, Pathology, research and practice.

[15]  D. Xie,et al.  CHD1L contributes to cisplatin resistance by upregulating the ABCB1–NF-κB axis in human non-small-cell lung cancer , 2019, Cell Death & Disease.

[16]  G. Song,et al.  Effects of luteolin on canine osteosarcoma: Suppression of cell proliferation and synergy with cisplatin , 2018, Journal of cellular physiology.

[17]  Jian-ping Guo,et al.  TIPE2 sensitizes osteosarcoma cells to cis‐platin by down‐regulating MDR1 via the TAK1‐ NF‐&kgr;B and ‐ AP‐1 pathways , 2018, Molecular immunology.

[18]  Michal Kielbik,et al.  Cisplatin-induced ERK1/2 activity promotes G1 to S phase progression which leads to chemoresistance of ovarian cancer cells , 2018, Oncotarget.

[19]  L. Alexopoulos,et al.  Selective cytotoxicity of the herbal substance acteoside against tumor cells and its mechanistic insights , 2018, Redox biology.

[20]  B. Zhai,et al.  Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells , 2017, PloS one.

[21]  Jianguo Wu,et al.  Hepatitis B virus PreS1 facilitates hepatocellular carcinoma development by promoting appearance and self-renewal of liver cancer stem cells. , 2017, Cancer letters.

[22]  Bo Huang,et al.  CHD1L Expression Increases Tumor Progression and Acts as a Predictive Biomarker for Poor Prognosis in Pancreatic Cancer , 2017, Digestive Diseases and Sciences.

[23]  Jianmin Li,et al.  Downregulation of DNA-PKcs suppresses P-gp expression via inhibition of the Akt/NF-κB pathway in CD133-positive osteosarcoma MG-63 cells. , 2016, Oncology reports.

[24]  Z. Cui,et al.  Knockdown of PARP-1 Inhibits Proliferation and ERK Signals, Increasing Drug Sensitivity in Osteosarcoma U2OS Cells , 2016, Oncology research.

[25]  Xiaohong Xu,et al.  Cell adhesion induces overexpression of chromodomain helicase/ATPase DNA binding protein 1-like gene (CHD1L) and contributes to cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma cells. , 2016, Leukemia research.

[26]  Su In Lee,et al.  Hypoxia-NOTCH1-SOX2 signaling is important for maintaining cancer stem cells in ovarian cancer , 2016, Oncotarget.

[27]  Yuchan Wang,et al.  CHD1L Regulates Cell Cycle, Apoptosis, and Migration in Glioma , 2015, Cellular and Molecular Neurobiology.

[28]  Xiaohui Wang,et al.  Secreted clusterin (sCLU) regulates cell proliferation and chemosensitivity to cisplatin by modulating ERK1/2 signals in human osteosarcoma cells , 2014, World Journal of Surgical Oncology.

[29]  David M. Thomas,et al.  Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  I. Shih,et al.  The roles of human sucrose nonfermenting protein 2 homologue in the tumor-promoting functions of Rsf-1. , 2008, Cancer research.